← Back to Analyst Consensus 
MLTX Buy
MoonLake Immunotherapeutics
Current Price —
Implied Upside —
Analysts 22
30-Day Momentum
▲ 0 upgrades / ▼ 0 downgrades / 1 reiterations from 1 firms
Next Earnings
Nov 17, 2026 (22 days)
Rating Timeline
| Date ▼ | Firm | Action | From → To Rating | Price Target | Firm Rating |
|---|---|---|---|---|---|
| Oct 5, 2026 | HC Wainwright & Co. | reiterate | Buy → Buy | — | 44% |
| Aug 13, 2026 | HC Wainwright & Co. | maintain | Buy → Buy | — | 44% |
| Jul 20, 2026 | HC Wainwright & Co. | reiterate | Buy → Buy | — | 44% |
| Jul 1, 2026 | Leerink Partners | maintain | Outperform → Outperform | — | 51% |
| Jun 9, 2026 | BTIG | reiterate | Buy → Buy | — | 52% |
| Jun 8, 2026 | HC Wainwright & Co. | reiterate | Buy → Buy | — | 44% |
| May 12, 2026 | Needham | maintain | Buy → Buy | — | 50% |
| May 11, 2026 | HC Wainwright & Co. | maintain | Buy → Buy | — | 44% |
| Mar 30, 2026 | BTIG | reiterate | Buy → Buy | — | 52% |
| Mar 23, 2026 | Wolfe Research | upgrade | Underperform → Outperform | — | 53% |
| Mar 19, 2026 | Rothschild & Co | upgrade | Neutral → Buy | — | 56% |
| Mar 11, 2026 | Clear Street | maintain | Buy → Buy | — | 48% |
| Mar 2, 2026 | RBC Capital | maintain | Sector Perform → Sector Perform | — | 55% |
| Mar 2, 2026 | HC Wainwright & Co. | maintain | Buy → Buy | — | 44% |
| Feb 26, 2026 | Needham | reiterate | Buy → Buy | $25 | 50% |
| Feb 24, 2026 | Oppenheimer | maintain | Outperform → Outperform | $35 | 52% |
| Feb 23, 2026 | BTIG | maintain | Buy → Buy | $30 | 52% |
| Feb 23, 2026 | Needham | maintain | Buy → Buy | $25 | 50% |
| Feb 20, 2026 | RBC Capital | maintain | Sector Perform → Sector Perform | $12 | 55% |
| Feb 9, 2026 | BTIG | reiterate | Buy → Buy | $24 | 52% |
| Feb 3, 2026 | HC Wainwright & Co. | reiterate | Buy → Buy | $32 | 44% |
| Jan 15, 2026 | Goldman Sachs | downgrade | Neutral → Sell | $10 | 54% |
| Jan 9, 2026 | HC Wainwright & Co. | reiterate | Buy → Buy | $32 | 44% |
| Jan 9, 2026 | BTIG | upgrade | Neutral → Buy | $24 | 52% |
| Nov 21, 2025 | HC Wainwright & Co. | maintain | Buy → Buy | $26 | 44% |
| Nov 3, 2025 | HC Wainwright & Co. | upgrade | Neutral → Buy | $30 | 44% |
| Oct 29, 2025 | Citigroup | downgrade | Neutral → Sell | $5 | 54% |
| Oct 2, 2025 | HC Wainwright & Co. | downgrade | Buy → Neutral | $0 | 44% |
| Sep 30, 2025 | Guggenheim | maintain | Buy → Buy | $20 | 52% |
| Sep 30, 2025 | Wedbush | maintain | Outperform → Outperform | $18 | 58% |
| Sep 30, 2025 | Citigroup | downgrade | Buy → Neutral | $5 | 54% |
| Sep 30, 2025 | Needham | maintain | Buy → Buy | $20 | 50% |
| Sep 29, 2025 | RBC Capital | downgrade | Outperform → Sector Perform | $10 | 55% |
| Sep 29, 2025 | BTIG | downgrade | Buy → Neutral | $85 | 52% |
| Aug 6, 2025 | Goldman Sachs | maintain | Buy → Buy | $82 | 54% |
| Jun 3, 2025 | RBC Capital | reiterate | Outperform → Outperform | $67 | 55% |
| May 19, 2025 | Wolfe Research | upgrade | Peer Perform → Outperform | $61 | 53% |
| May 13, 2025 | Needham | reiterate | Buy → Buy | $66 | 50% |
| Apr 30, 2025 | Needham | reiterate | Buy → Buy | $66 | 50% |
| Mar 18, 2025 | RBC Capital | initiate | — → Outperform | $67 | 55% |
| Feb 27, 2025 | Goldman Sachs | maintain | Buy → Buy | $73 | 54% |
| Feb 27, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $100 | 44% |
| Feb 27, 2025 | Needham | maintain | Buy → Buy | $66 | 50% |
| Jan 17, 2025 | Goldman Sachs | upgrade | Neutral → Buy | $82 | 54% |
| Jan 10, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $100 | 44% |
| Nov 14, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $100 | 44% |
| Nov 8, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $100 | 44% |
| Oct 15, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $100 | 44% |
| Sep 23, 2024 | Cantor Fitzgerald | reiterate | — → Overweight | $0 | 50% |
| Sep 12, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $100 | 44% |
Price Target Trend
May 27, 2026 Oct 26, 2026
EPS Estimates
0y —
0q —
+1y —
+1q —
Cross-Platform Signals
No cross-platform signals in the last 90 days